公开(公告)号：US4965263A

公开(公告)日：1990-10-23

申请号：US310505

申请日：1989-02-14

申请人： Takashi Nishina ,  Joji Kamiya ,  Yasuhito Tanaka ,  Tsutomu Katakami ,  Nobuyuki Fukazawa ,  Hajime Iizuka ,  Takuo Nakano

发明人： Takashi Nishina ,  Joji Kamiya ,  Yasuhito Tanaka ,  Tsutomu Katakami ,  Nobuyuki Fukazawa ,  Hajime Iizuka ,  Takuo Nakano

IPC分类号： C07D237/04 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12

CPC分类号： C07D401/12 ,  C07D237/04 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12

摘要： This invention relates to pyridazinone derivatives of the general formula: ##STR1## [wherein R.sup.1 stands for a hydrogen atom or a lower alkyl group; R.sup.2 for a hydrogen atom or a lower alkyl group; and A for (i) a ring selected from a benzene ring, a furan ring, a thiophene ring and a pyridine ring (on which ring 1-3 substituents or atoms selected from amino groups, nitro groups, lower alkanoylamino groups, hydroxyl groups, lower alkanoyloxy groups, sulfamoyl groups and halogen atoms may be present), or (ii) a grouping of the formula: ##STR2## (wherein R.sup.3 stands for a hydrogen atom, a lower alkyl group, a phenyl(lower)alkyl, a hydroxyphenyl(lower)alkyl group, a lower alkylmercapto(lower)alkyl group, a benzylmercapto(lower)alkyl group, a guanidino(lower)alkyl group, a nitroguanidino(lower)alkyl group, an indolyl(lower)alkyl group, a carbamoyl(lower)alkyl group or a carboxy(lower)alkyl group, R.sup.4 for a hydrogen atom or a lower alkyl group, R.sup.5 for a hydrogen atom, a lower alkyl group, a lower alkanoyl group, a benzoyl or a benzyloxycarbonyl group, and R.sup.3 and R.sup.4 may be combined to form a grouping of the formula: ##STR3## which forms a ring), or (iii) a grouping of the formula: ##STR4## (wherein R.sup.6, R.sup.7 and R.sup.8 each stand for a hydrogen atom or a lower alkyl group, B is an oxygen atom or a sulfur atom, R.sup.9 stands for a hydrogen atom or a lower alkanoyl group, and n is 0 or 1)].

公开(公告)号：US4639451A

公开(公告)日：1987-01-27

申请号：US504039

申请日：1983-06-03

申请人： Tsutomu Katakami ,  Nobuyuki Fukazawa ,  Hajime Iizuka ,  Takashi Nishina ,  Joji Kamiya ,  Yasuhito Tanaka ,  Takuo Nakano

发明人： Tsutomu Katakami ,  Nobuyuki Fukazawa ,  Hajime Iizuka ,  Takashi Nishina ,  Joji Kamiya ,  Yasuhito Tanaka ,  Takuo Nakano

IPC分类号： C07D237/04 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  A61K31/50

CPC分类号： C07D401/12 ,  C07D237/04 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12

摘要： This invention relates to pyridazinone derivatives of the general formula: ##STR1## [wherein R.sup.1 stands for a hydrogen atom or a lower alkyl group; R.sup.2 for a hydrogen atom or a lower alkyl group; and A for (i) a ring selected from a benzene ring, a furan ring, a thiophene ring and a pyridine ring (on which ring 1-3 substituents or atoms selected from amino groups, nitro groups, lower alkanoylamino groups, hydroxyl groups, lower alkanoyloxy groups, sulfamoyl groups and halogen atoms may be present), or (ii) a grouping of the formula: ##STR2## (wherein R.sup.3 stands for a hydrogen atom, a lower alkyl group, a phenyl(lower)alkyl, a hydroxyphenyl(lower)alkyl group, a lower alkylmercapto(lower)alkyl group, a benzylmercapto(lower)alkyl group, a guanidino(lower)alkyl group, a nitroguanidino(lower)alkyl group, an indolyl(lower)alkyl group, a carbamoyl(lower)alkyl group or a carboxy(lower)alkyl group, R.sup.4 for a hydrogen atom or a lower alkyl group, R.sup.5 for a hydrogen atom, a lower alkyl group, a lower alkanoyl group, a benzoyl or a benzyloxycarbonyl group, and R.sup.3 and R.sup.4 may be combined to form a grouping of the formula: ##STR3## which forms a ring), or (iii) a grouping of the formula: ##STR4## (wherein R.sup.6, R.sup.7 and R.sup.8 each stand for a hydrogen atom or a lower alkyl group, B is an oxygen atom or a sulfur atom, R.sup.9 stands for a hydrogen atom or a lower alkanoyl group, and n is 0 or 1)].

摘要翻译： PCT No.PCT / JP82 / 00415 Sec。 371日期：1983年6月3日 102（e）日期1983年6月3日PCT提交1982年10月20日PCT公布。 第WO83 / 01447号公报 日本1983年4月28日。本发明涉及以下通式的哒嗪酮衍生物：其中R1代表氢原子或低级烷基; R2为氢原子或低级烷基; A为（i）选自苯环，呋喃环，噻吩环和吡啶环的环（其中1-3个取代基或选自氨基，硝基，低级烷酰基氨基，羟基， 低级烷酰氧基，氨磺酰基和卤素原子可以存在），或（ii）下式的基团：其中R3代表氢原子，低级烷基，苯基（低级）烷基，羟基苯基 （低级）烷基，低级烷基巯基（低级）烷基，苄基巯基（低级）烷基，胍基（低级）烷基，硝基胍基（低级）烷基，吲哚基（低级）烷基，氨基甲酰基 低级）烷基或羧基（低级）烷基，R4表示氢原子或低级烷基，R5表示氢原子，低级烷基，低级链烷酰基，苯甲酰基或苄氧基羰基，R3和 R4可以组合以形成下式的分组：形成环的），或（iii）下式的分组：（ 其中R6，R7和R8各自代表氢原子或低级烷基，B是氧原子或硫原子，R9代表氢原子或低级烷酰基，n是0或1）]。

公开(公告)号：US4521415A

公开(公告)日：1985-06-04

申请号：US454021

申请日：1982-12-28

申请人： Tsutomu Katakami ,  Nobuyuki Fukazawa ,  Hajime Iizuka ,  Takashi Nishina ,  Joji Kamiya ,  Yasuhito Tanaka ,  Takuo Nakano

发明人： Tsutomu Katakami ,  Nobuyuki Fukazawa ,  Hajime Iizuka ,  Takashi Nishina ,  Joji Kamiya ,  Yasuhito Tanaka ,  Takuo Nakano

IPC分类号： A61K31/50 ,  A61P7/02 ,  A61P9/12 ,  C07D237/04 ,  C07D401/12 ,  C07D403/12

CPC分类号： C07D401/12 ,  C07D237/04 ,  C07D403/12

摘要： 6-(Substituted phenyl)-4,5-dihydro-3(2H)-pyridazinone compounds possessing strong platelet aggregation inhibiting activity and blood pressure depressing activity, having the general formula: ##STR1## wherein R.sup.1 is hydrogen or lower alkyl; R.sup.2 is hydrogen, lower alkyl, lower alkylthio or the grouping R.sup.5 --NH-- where R.sup.5 is lower alkyl; R.sup.3 is phenyl, pyridyl, benzyl, lower alkyl or a substituted phenyl group carrying at any desired position on the benzene ring thereof the grouping: ##STR2## where R.sup.1 has the same meaning as given above; R.sup.4 is hydrogen or halogen; n is 0 or 1; and when both R.sup.2 and R.sup.3 are lower alkyl groups, R.sup.2 and R.sup.3 may be combined together with the bridging member ##STR3## where m is 2 or 3, as well as physiologically acceptable acid-addition salts thereof, and processes for preparing them.

摘要翻译： 具有强烈的血小板聚集抑制活性和降低血压的6-（取代的苯基）-4,5-二氢-3（2H） - 哒嗪酮化合物，具有以下通式：其中R 1为氢或低级烷基 ; R2是氢，低级烷基，低级烷硫基或分组R5-NH-，其中R5是低级烷基; R3是苯基，吡啶基，苄基，低级烷基或在其苯环上的任何所需位置携带的取代苯基，其分子式如下：其中R 1具有与上述相同的含义; R4是氢或卤素; n为0或1; 当R 2和R 3均为低级烷基时，R 2和R 3可以与m为2或3的桥连基团以及其生理上可接受的酸加成盐组合在一起，以及制备方法 他们。

公开(公告)号：US4523011A

公开(公告)日：1985-06-11

申请号：US594303

申请日：1984-03-28

申请人： Tsutomu Katakami ,  Nobuyuki Fukazawa ,  Hajime Iizuka ,  Takashi Nishina ,  Joji Kamiya ,  Yasuhito Tanaka ,  Takuo Nakano

发明人： Tsutomu Katakami ,  Nobuyuki Fukazawa ,  Hajime Iizuka ,  Takashi Nishina ,  Joji Kamiya ,  Yasuhito Tanaka ,  Takuo Nakano

IPC分类号： A61K31/50 ,  A61P7/02 ,  A61P9/12 ,  C07D237/04 ,  C07D401/12 ,  C07D403/12

CPC分类号： C07D401/12 ,  C07D237/04 ,  C07D403/12

摘要： 6-(Substituted phenyl)-4,5-dihydro-3(2H)-pyridazinone compounds possessing strong platelet aggregation inhibiting activity and blood pressure depressing activity, having the general formula: ##STR1## wherein R.sup.1 is hydrogen or lower alkyl; R.sup.2 is hydrogen, lower alkyl, lower alkylthio or the grouping R.sup.5 --NH-- where R.sup.5 is lower alkyl; R.sup.3 is phenyl, pyridyl, benzyl, lower alkyl or a substituted phenyl group carrying at any desired position on the benzene ring thereof the grouping: ##STR2## where R.sup.1 has the same meaning as given above; R.sup.4 is hydrogen or halogen; n is 0 or 1; and when both R.sup.2 and R.sup.3 are lower alkyl groups, R.sup.2 and R.sup.3 may be combined together with the bridging member ##STR3## between them to form the structure: ##STR4## where m is 2 or 3, as well as physiologically acceptable acid-addition salts thereof, and processes for preparing them.

公开(公告)号：US20140302082A1

公开(公告)日：2014-10-09

申请号：US14009049

申请日：2012-03-30

申请人： Takaji Wakita ,  Tomoko Date ,  Yasuhito Tanaka ,  Masashi Mizokami

发明人： Takaji Wakita ,  Tomoko Date ,  Yasuhito Tanaka ,  Masashi Mizokami

IPC分类号： C12N7/00 ,  C12Q1/70 ,  C07K16/08

CPC分类号： C12N7/00 ,  A61K39/00 ,  A61K39/12 ,  C07K14/005 ,  C07K16/082 ,  C07K16/109 ,  C12N15/86 ,  C12N2770/24221 ,  C12N2770/24222 ,  C12N2770/24231 ,  C12N2770/24234 ,  C12N2770/24243 ,  C12N2770/24251 ,  C12Q1/707 ,  C12Q2600/136 ,  C12Q2600/156

摘要： A subgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and a fullgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and infectious HCV particle-producing ability, each derived from a novel HCV of genotype 1b, are provided. Particularly, a subgenomic replicon RNA (nucleic acid) and a fullgenomic replicon RNA (nucleic acid), each derived from an HCV genome of the NC1 strain which is a novel HCV genotype 1b isolated from a patient with acute severe hepatitis C, are provided.

摘要翻译： 提供了具有优异的自主复制能力的亚基因组复制子RNA（核酸）和具有优异的自主复制能力和感染性HCV颗粒产生能力的全基因组复制子RNA（核酸），各自源自基因型1b的新型HCV。 特别地，提供了从NC1菌株的HCV基因组衍生的亚基因组复制子RNA（核酸）和全基因组复制子RNA（核酸），其是从急性重症丙型肝炎患者分离的新型HCV基因型1b。

公开(公告)号：US20110160252A1

公开(公告)日：2011-06-30

申请号：US12999055

申请日：2009-06-18

申请人： Masashi Mizokami ,  Yasuhito Tanaka ,  Masaya Sugiyama ,  Masayuki Sudoh

发明人： Masashi Mizokami ,  Yasuhito Tanaka ,  Masaya Sugiyama ,  Masayuki Sudoh

IPC分类号： A61K31/44 ,  C07C229/34 ,  A61K31/195 ,  C07D213/55 ,  A61P31/12

CPC分类号： A61K31/13 ,  A61K31/165 ,  A61K31/201 ,  A61K31/381 ,  A61K31/405 ,  A61K31/4406 ,  A61K31/4418

摘要： First, the present inventors assessed the effect of the compound represented by formula (III) below on Huh-7 cells infected with HBV, and demonstrated that the compound alone had an anti-HBV effect in vitro.Formula (III) Then, the present inventors revealed that the HBV replication-suppressing effect of PEG-IFN is enhanced in chimeric mice having a human liver infected with genotype C or A HBV when PEG-IFN is used in combination with the compound represented by formula (III) above. The present inventors also revealed that the HBV replication-suppressing effect of Entecavir is enhanced in chimeric mice having a human liver infected with genotype C HBV (wild-type and Entecavir-resistant strains) when Entecavir is used in combination with the compound represented by formula (III) above. In addition, the present inventors revealed that the compound represented by formula (III) above exerts the anti-HBV effect not only against wild-type HBV strains but also against Entecavir- and/or Lamivudine-resistant HBV strains.

摘要翻译： 首先，本发明人评估了下述式（III）表示的化合物对HBV感染的Huh-7细胞的作用，并证明该化合物在体外具有抗HBV作用。 式（III）然后，本发明人揭示了当将PEG-IFN与由下列化合物组合使用时，将具有基因型C或A HBV感染的人肝的嵌合小鼠中的PEG-IFN的HBV复制抑制作用增强 上述式（III）。 本发明人还发现，当恩替卡韦与式（I）表示的化合物组合使用时，恩替卡韦的HBV复制抑制作用在具有感染基因型C HBV（野生型和恩替卡韦抗性菌株）的人肝脏的嵌合小鼠中得到增强 （三）。 此外，本发明人发现，上述式（III）表示的化合物不仅对抗野生型HBV株而且对依替卡韦和/或拉米夫定耐药的HBV株产生抗HBV作用。

公开(公告)号：US20110126791A1

公开(公告)日：2011-06-02

申请号：US13055222

申请日：2008-07-25

申请人： Yasuhito Tanaka ,  Hisanaga Yokoyama

发明人： Yasuhito Tanaka ,  Hisanaga Yokoyama

IPC分类号： F01L3/02 ,  C21D9/00 ,  C21D1/00 ,  C21D6/00 ,  C22F1/10

CPC分类号： C22C38/02 ,  B21K1/22 ,  C21D1/10 ,  C21D1/42 ,  C21D6/00 ,  C21D9/00 ,  C21D2211/001 ,  C21D2221/00 ,  F01L1/0532 ,  F01L1/143 ,  F01L3/00 ,  F01L3/02 ,  F01L3/08 ,  F01L3/20 ,  F01L2101/00 ,  F01L2103/00 ,  F01L2820/01 ,  Y02P10/253

摘要： Object of the Invention The invention provides a forged exhaust poppet valve and a method of solution heat treating the same, in which only a predetermined portion of the valve is subjected to the solution heat treatment so as to provide the seat portion of the valve with satisfactory wear resistance, and a predetermined transitional neck-stem region with satisfactory high-temperature creep strength.Means for Achieving the Object An exhaust poppet valve (10) comprises a head portion (12) which has a seat portion (14) on the outer periphery thereof and is integral with the diametrically tapered neck portion (16) of a stem portion (18) of the valve. Using a radio-frequency heating apparatus, a solution heat treatment is given to a predetermined transitional region (A) defined between the neck and stem portions that is exposed to exhaust air during a valve opening period so that the grain size in the region (A) is controlled not to exceed ASTM 10. Thus, not only required high-temperature creep strength is secured in the transitional neck-shaft region (A) but also necessary hardness (wear resistance) is secured in the seat portion (14) of the valve (10), thereby rendering the exhaust poppet valve highly durable.

摘要翻译： 发明目的本发明提供了一种锻造排气提升阀及其热处理方法，其中仅对阀的预定部分进行固溶热处理，以使阀的座部分具有令人满意的 耐磨性以及具有令人满意的高温蠕变强度的预定的过渡颈部区域。 用于实现对象的装置排气提升阀（10）包括头部（12），头部（12）在其外周上具有座部（14），并与杆部（18）的直径锥形颈部（16）成一体 ）。 使用射频加热装置，在限定在颈部和茎部之间的预定过渡区域（A）进行固溶热处理，其在阀打开期间暴露于排气中，使得区域（A ）被控制为不超过ASTM 10.因此，不仅在过渡颈部轴区域（A）中确保了所需的高温蠕变强度，而且确保了必要的硬度（耐磨性）在座椅部分（14）中 阀（10），从而使排气提升阀高度耐用。

公开(公告)号：US07100754B2

公开(公告)日：2006-09-05

申请号：US10997877

申请日：2004-11-29

申请人： Yasuhito Tanaka

发明人： Yasuhito Tanaka

IPC分类号： F16D15/00

CPC分类号： F16H55/36 ,  F16H2055/366

摘要： A pulley unit made by interposing a one-way clutch in an annular space between a pulley and an axial body providing a deep groove ball bearing on a base end side of the one-way clutch, and a roller bearing on the free end side; setting an inner rolling surface of a roller of the one-way clutch to be an outer diameter surface of the axial body and an inner rolling surface of a rolling member of the roller bearing to be an outer diameter surface of the axial body. The pulley unit permits easy position setting of the pulley, so that stabilized lock and free operation can be expected and productivity can be improved.

摘要翻译： 1.一种滑轮单元，其通过在单向离合器的基端侧的滑轮与轴向体之间的环形空间中插入单向离合器和在自由端侧的滚子轴承， 将单向离合器的辊的内侧滚动面设定为轴向体的外径面，将滚子轴承的滚动体的内侧滚动面设定为轴向体的外径面。 滑轮单元允许滑轮的容易位置设置，从而可以预期稳定的锁定和自由操作，并且可以提高生产率。

公开(公告)号：US06721238B2

公开(公告)日：2004-04-13

申请号：US09996418

申请日：2001-11-29

申请人： Yasuhito Tanaka ,  Yoshihiro Muto

发明人： Yasuhito Tanaka ,  Yoshihiro Muto

IPC分类号： G11B1100

CPC分类号： G11B11/10586 ,  G11B11/10584 ,  Y10T428/1121

摘要： A magneto-optical recording medium for recording and reproducing carriers by laser beam irradiation includes a first magnetic layer which is magnetized in the in-plane direction at room temperature and is perpendicularly magnetized at a predetermined temperature T1 or more; a second magnetic layer which is in contact with the first magnetic layer, has a Curie temperature Tc2 higher than the predetermined temperature T1, and has in-plane magnetic anisotropy up to the Curie temperature Tc2; a third magnetic layer which has a Curie temperature Tc3 higher than the predetermined temperature T1 and has perpendicular magnetic anisotropy at least in a predetermined range of a temperature distribution of the magneto-optical recording medium during laser beam irradiation when reproducing; and a rare earth metal layer formed between the third magnetic layer and the second magnetic layer.

摘要翻译： 用于通过激光束照射来记录和再现载体的磁光记录介质包括在室温下在面内方向被磁化并在预定温度T1或更高的温度下垂直磁化的第一磁性层; 与第一磁性层接触的第二磁性层具有高于预定温度T1的居里温度Tc2，具有高达居里温度Tc2的面内磁各向异性; 具有比预定温度T1高的居里温度Tc3的第三磁性层，并且在再现时在激光束照射期间至少在磁光记录介质的温度分布的预定范围内具有垂直的磁各向异性; 以及形成在第三磁性层和第二磁性层之间的稀土金属层。

公开(公告)号：US06207151B1

公开(公告)日：2001-03-27

申请号：US08259152

申请日：1994-06-13

申请人： Yukio Shimazaki ,  Nobuhiro Kawashima ,  Miki Suzuki ,  Yasuhito Tanaka ,  Ryo Tanaka ,  Kiyoshi Sakai ,  Hisahiro Ishiwari

发明人： Yukio Shimazaki ,  Nobuhiro Kawashima ,  Miki Suzuki ,  Yasuhito Tanaka ,  Ryo Tanaka ,  Kiyoshi Sakai ,  Hisahiro Ishiwari

IPC分类号： A61K3849

CPC分类号： A61K38/49 ,  A61K47/34 ,  A61K47/36 ,  A61K47/42

摘要： Aqueous protein-containing solutions, in which a protein is dissolved at a high concentration at a pH near the isoelectric point of the protein by adding an anionic polymer or a salt thereof to the solution. Pharmaceutical formulations using a physiologically active protein are prepared using this technique.

摘要翻译： 含有蛋白质的溶液，其中蛋白质通过向溶液中加入阴离子聚合物或其盐，在接近蛋白质等电点的pH下以高浓度溶解。 使用该技术制备使用生理活性蛋白质的药物制剂。